Skip to content
中文产业新闻评分63Chinese source

艾伯维 c-Met ADC telisotuzumab adizutecan 获 FDA 结直肠癌和非小细胞肺癌突破性疗法认定

艾伯维的c-Met ADC获FDA结直肠癌和非小细胞肺癌突破性疗法认定

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.